(Ebook) Evolution of Translational Omics : Lessons Learned and the Path Forward by Institute of Medicine; Board on Health Sciences Policy; Board on Health Care Services; Committee on the Review of Omics-Based Tests for Predicting Patient Outcomes in Clinical Trials; Gilbert S. Omenn; Sharly J. Nass; Christine M. Micheel ISBN 9780309224192, 0309224195

(Ebook) Evolution of Translational Omics : Lessons Learned and the Path Forward by Institute of Medicine; Board on Health Sciences Policy; Board on Health Care Services; Committee on the Review of Omics-Based Tests for Predicting Patient Outcomes in Clinical Trials; Gilbert S. Omenn; Sharly J. Nass; Christine M. Micheel ISBN 9780309224192, 0309224195

Technologies collectively called omics enable simultaneous measurement of an enormous number of biomolecules; for example, genomics investigates thousands of DNA sequences, and proteomics examines large numbers of proteins. Scientists are using these technologies to develop innovative tests to detect disease and to predict a patient's likelihood of responding to specific drugs. Following a recent case involving premature use of omics-based tests in cancer clinical trials at Duke University, the NCI requested that the IOM establish a committee to recommend ways to strengthen omics-based test development and evaluation. This report identifies best practices to enhance development, evaluation, and translation of omics-based tests while simultaneously reinforcing steps to ensure that these tests are appropriately assessed for scientific validity before they are used to guide patient treatment in clinical trials.